Fulgent Genetics (FLGT) Cash from Investing Activities (2015 - 2026)

Fulgent Genetics (FLGT) has 12 years of Cash from Investing Activities data on file, last reported at $10.9 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 60.55% year-over-year to $10.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $94.6 million (up 471.04% YoY) and the FY2025 annual result came in at $111.4 million, up 290.86% from the prior year.
• Cash from Investing Activities eased to $10.9 million in Q1 2026 per FLGT's latest filing, from $11.2 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $53.4 million in Q2 2025, with the low at -$213.7 million in Q2 2022.
• Average Cash from Investing Activities over 5 years is -$9.3 million, with a median of $9.0 million recorded in 2024.
• The widest YoY moves for Cash from Investing Activities: up 766.42% in 2024, down 983.74% in 2024.
• Fulgent Genetics' Cash from Investing Activities stood at -$92.6 million in 2022, then soared by 126.21% to $24.3 million in 2023, then slumped by 213.12% to -$27.5 million in 2024, then surged by 140.63% to $11.2 million in 2025, then dropped by 1.93% to $10.9 million in 2026.
• Business Quant data shows FLGT's Cash from Investing Activities at $10.9 million in Q1 2026, $11.2 million in Q4 2025, and $19.1 million in Q3 2025.